49 mins ago · Hong Kong
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
What's happening
SignalsMonitor is following this as a politics story. South China Morning Post Asia is the outlet attached so far. The reports are tied to Hong Kong. The first report grouped here was at 2 Nov 2026, 00:30 UTC. The headline in use is “Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
Reported by 1 outlet
- South China Morning Post
- South China Morning PostDrug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner